TABLE 4.

AUC calculations of ROC analysis for patients with CCA and iCCA versus HCC, benign hepatobiliary diseases, chronic hepatitis B, and healthy individuals.

	n	ITIH5			CA19‐9			ITIH5 + CA19‐9
		AUC	95%CI		AUC	95%CI		AUC	95%CI
CCA versus controls
CCA‐HCC	65/30	0.839	0.756	0.923	0.801	0.710	0.892	0.896	0.827	0.965
CCA‐Benign	65/55	0.848	0.771	0.925	0.741	0.647	0.835	0.831	0.752	0.909
CCA‐CHB	65/30	0.851	0.762	0.940	0.853	0.778	0.928	0.929	0.876	0.982
CCA‐Healthy	65/32	0.851	0.758	0.945	0.915	0.860	0.969	0.962	0.931	0.994
CCA‐NCCA	65/147	0.848	0.789	0.907	0.814	0.709	0.879	0.867	0.817	0.918
iCCA versus controls
iCCA‐HCC	13/30	0.921	0.841	1.000	0.704	0.513	0.895	0.954	0.897	1.000
iCCA‐Benign	13/55	0.919	0.854	0.984	0.655	0.480	0.829	0.898	0.825	0.971
iCCA‐CHB	13/30	0.910	0.825	0.996	0.756	0.571	0.942	0.954	0.898	1.000
iCCA‐Healthy	13/32	0.904	0.818	0.990	0.825	0.655	0.994	0.976	0.941	1.000
iCCA‐NCCA	13/147	0.914	0.862	0.966	0.722	0552	0.891	0.920	0.874	0.966

Abbreviations: AUC, area under the receiver‐operating characteristic curve; Benign, benign hepatobiliary diseases; CCA, cholangiocarcinoma; CHB, chronic hepatitis B; HCC, hepatocellular carcinoma; Healthy, healthy individuals; iCCA, intrahepatic cholangiocarcinoma; NCCA, the total patients without CCA.